CN101300341B - Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation - Google Patents
Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation Download PDFInfo
- Publication number
- CN101300341B CN101300341B CN2006800406235A CN200680040623A CN101300341B CN 101300341 B CN101300341 B CN 101300341B CN 2006800406235 A CN2006800406235 A CN 2006800406235A CN 200680040623 A CN200680040623 A CN 200680040623A CN 101300341 B CN101300341 B CN 101300341B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus
- milk
- composition
- bacterium
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000894006 Bacteria Species 0.000 title claims abstract description 78
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 title abstract description 102
- 235000014655 lactic acid Nutrition 0.000 title abstract description 51
- 239000004310 lactic acid Substances 0.000 title abstract description 5
- 230000004957 immunoregulator effect Effects 0.000 title abstract 5
- 235000014101 wine Nutrition 0.000 title description 10
- 238000000855 fermentation Methods 0.000 title description 8
- 230000004151 fermentation Effects 0.000 title description 8
- 241000186660 Lactobacillus Species 0.000 claims abstract description 90
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 49
- 230000000694 effects Effects 0.000 claims description 72
- 230000007365 immunoregulation Effects 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 8
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 7
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 7
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000037213 diet Effects 0.000 claims description 6
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 claims description 5
- 238000005516 engineering process Methods 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 12
- 230000036737 immune function Effects 0.000 abstract description 7
- 230000003213 activating effect Effects 0.000 abstract 1
- 102000013462 Interleukin-12 Human genes 0.000 description 26
- 108010065805 Interleukin-12 Proteins 0.000 description 26
- 229940117681 interleukin-12 Drugs 0.000 description 23
- 241000196324 Embryophyta Species 0.000 description 19
- 238000004519 manufacturing process Methods 0.000 description 19
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 17
- 244000005700 microbiome Species 0.000 description 17
- 239000000047 product Substances 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 230000036039 immunity Effects 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 235000013336 milk Nutrition 0.000 description 9
- 239000008267 milk Substances 0.000 description 9
- 210000004080 milk Anatomy 0.000 description 9
- 210000000822 natural killer cell Anatomy 0.000 description 9
- 238000000926 separation method Methods 0.000 description 8
- 244000068988 Glycine max Species 0.000 description 7
- 235000010469 Glycine max Nutrition 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 238000012216 screening Methods 0.000 description 6
- 235000013599 spices Nutrition 0.000 description 6
- 210000004988 splenocyte Anatomy 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 235000013311 vegetables Nutrition 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 240000001929 Lactobacillus brevis Species 0.000 description 5
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000011514 vinification Methods 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 235000009754 Vitis X bourquina Nutrition 0.000 description 4
- 235000012333 Vitis X labruscana Nutrition 0.000 description 4
- 240000006365 Vitis vinifera Species 0.000 description 4
- 235000014787 Vitis vinifera Nutrition 0.000 description 4
- 235000013353 coffee beverage Nutrition 0.000 description 4
- 235000015140 cultured milk Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 235000015040 sparkling wine Nutrition 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 235000015203 fruit juice Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 210000000697 sensory organ Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 229960003487 xylose Drugs 0.000 description 3
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 241000345998 Calamus manan Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000186684 Lactobacillus pentosus Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 235000013405 beer Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 235000021185 dessert Nutrition 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019990 fruit wine Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000021577 malt beverage Nutrition 0.000 description 2
- 239000001814 pectin Substances 0.000 description 2
- 235000010987 pectin Nutrition 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 210000003024 peritoneal macrophage Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000012950 rattan cane Nutrition 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000021262 sour milk Nutrition 0.000 description 2
- 235000015041 whisky Nutrition 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000555678 Citrus unshiu Species 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010013183 Dislocation of vertebra Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 238000006424 Flood reaction Methods 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241000269951 Labridae Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000013124 brewing process Methods 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- -1 fatty acid ester Chemical class 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000021552 granulated sugar Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Dairy Products (AREA)
Abstract
The invention relates to a bacterium belonging to the genus Lactobacillus having an immunoregulatory activity, a composition containing the same, and a method of efficiently isolating a lactic acid bacterium having an immunoregulatory activity. The bacterium belonging to the genus Lactobacillus of the invention has an immunoregulatory activity, and if the composition of the invention is taken or the like, a decrease in immune function can be suppressed by activating the immune function. Further, according to the invention, a lactic acid bacterium having an immunoregulatory activity can be efficiently obtained.
Description
Technical field
The present invention relates to have immunoregulation effect the lactobacillus bacterium, contain the composition of this bacterium and have the efficient separation method of the milk-acid bacteria of immunoregulation effect.
Background technology
Known milk-acid bacteria has useful physiologically actives such as whole intestines effect, immunity effect effect, and is the starting material with healthy functions, so ordinary consumer is also very high to its cognition degree.The great majority that this kind has a milk-acid bacteria of useful physiologically active are isolating from the raw-material milk-acid bacteria of animal from cultured milk prod, enteron aisle.
In addition, in the vegetalitas milk-acid bacteria that with the material of vegetable origin is separation source, also found to have the bacterial strain of immunity effect effect.For example, put down in writing milk-acid bacteria plant lactobacillus (Lactobacillusplantarum) L-137 strain in the Japanese kokai publication hei 10-167972 communique (open day: put down on June 23rd, 10) with immunity effect effect.And known isolating short lactobacillus (Lactobacillus brevis) Labre strain from the traditional salted vegetables class in capital of a country " pickled radiss salted vegetables " (Japanese original name: " The ぐ I "), isolating Lactobacillus pentosus (Lactobacillus pentosus) DA74N strain etc. also has immunity effect effect [reference: the special fair 7-55908 communique of (1) Japan (open day: put down on July 26th, 6) from " purple perilla floods " (Japanese original name: " ば Stains け "), (2) Pasken Journal 15.21-26,2002, bank Tun, little Kubo AOI (Japanese original name: ぁ お い), Chi Gu smokes, fan paddy ERI (Japanese original name: え り), rattan Tian Zhe also, bank Tian Gangtai youth: be used for the selected screening 1 of useful milk-acid bacteria) (the Japanese original name: the sour bacterium Election of useful breast decides め ス Network リ one ニ Application グ 1)) external (in vitro) immunity effect effect of human body peripheral blood vegetalitas milk-acid bacteria, (3) the 6th intestinal bacterium association (2002.05.30-31) main ideas, Chi Gu smokes, bank Tun, fan paddy ERI (Japanese original name: え り), little Kubo AOI (Japanese original name: ぁ お い), rattan Tian Zhe also, bank Tian Gangtai youth)].
Known is the confidential relation of having brewageed of the vegetalitas milk-acid bacteria of separation source and salted vegetables class, drinks with the material of vegetable origin, can separate a large amount of bacterium from brewage operation.Except that above-mentioned, also there is bacterial strain with valuable physiologically actives such as immunity effect effects, for example, brewage in the bacterial strain isolating the wine making operation of operation, that cross frequence is high from drinks and can enumerate plant lactobacillus.But, brewage isolating bacterium the operation for this kind from drinks, mainly the research of carrying out is relevant its effect in brewing process, it is to roles such as fragrance, for bacterium itself effect that organism produced is not studied substantially.Therefore, hope is brewageed from drinks and is found the bacterial strain with valuable physiologically active the operation in the isolating milk-acid bacteria.In addition, produce unique fermented flavour when using the vegetalitas milk-acid bacteria sometimes, so, need consider the problem of sense organ aspect sometimes according to the food variety of making.
Summary of the invention
The present invention is purpose in view of above-mentioned present situation with the method that provides the milk-acid bacteria with immunoregulation effect, the composition that contains this bacterium and separation to have the milk-acid bacteria of immunoregulation effect.
The present inventor is for solving related problem, measured its immunoregulation effect for isolating milk-acid bacteria the product of brewageing operation from drinks, for the milk-acid bacteria that belongs to plant lactobacillus and short lactobacillus, measured its immunoregulation effect in further detail from wherein selecting.It found that this milk-acid bacteria has strong immunoregulation effect, and uses the tunning of this milk-acid bacteria to present good fragrance, thereby has finished the present invention.
Specifically, for isolating milk-acid bacteria the product of brewageing operation from drinks, the comparative result of Th1 cytokines interleukin 12 (below be abbreviated as " IL-12 ") inducibility, find that but high efficiency separation has the milk-acid bacteria of immunoregulation effect, when particularly also having found to use the bacterial strain that belongs to plant lactobacillus and short lactobacillus that the peritoneal macrophage by the mouse preparation is carried out extracorporeal treatment, the generation of IL-12 is increased.And also confirmed in mouse peritoneal, to heat the vivo medicine-feeding of bacterium liquid, also can induce the generation of Th1 cytokines IL-12.
Promptly the present invention relates to the lactobacillus bacterium with immunoregulation effect that contained in the composition that contains microorganism in the drinks manufacturing process, the composition that particularly contains microorganism is a fermentation liquid, and drinks manufacturing process is the brewing grape wine operation.
In addition, the present invention relates to have the plant lactobacillus (Lactobacillusplantarum) or the short lactobacillus (Lactobacillus brevis) of immunoregulation effect.
And among the present invention, the plant lactobacillus with immunoregulation effect is that plant lactobacillus SAM2446 strain (FERM ABP-10438) or short lactobacillus are short lactobacillus SAM2447 strain (FERM ABP-10439).
The invention still further relates to the composition with immunoregulation effect, it contains the lactobacillus bacterium with immunoregulation effect that is contained in the composition that contains microorganism in the drinks manufacturing process.Particularly described composition is diet product or pharmaceuticals.
The present invention also further relates to the method for separating the milk-acid bacteria with immunoregulation effect, and it comprises the operation of separate microorganism in the composition that contains microorganism from drinks manufacturing process, the operation of immunoregulation effect of measuring isolating each microorganism of institute and the operation of screening the strong milk-acid bacteria of immunoregulation effect.The composition that particularly contains microorganism is a fermentation liquid, and drinks manufacturing process is the brewing grape wine operation.
Description of drawings
Fig. 1 represents to measure with 12 kinds of milk-acid bacterias serum il-12 concentration result after the administration in mouse peritoneal.
Fig. 2 represents the 16SrRNA gene order of the SAM2446 strain through understanding.The portion of rolling off the production line represents the sequence distinct portions with plant lactobacillus JCM1149T (ATCC14917).
Fig. 3 represents the 16SrRNA gene order of the SAM2447 strain through understanding.The portion of rolling off the production line represents the sequence distinct portions with short lactobacillus JCM1059T (ATCC14869).
Fig. 4 represents the active measurement result of NK.
Fig. 5 represents the measurement result of IFN-γ concentration.
Embodiment
＜lactobacillus bacterium 〉
The lactobacillus bacterium is a kind of of milk-acid bacteria, the present invention relates to the lactobacillus bacterium with immunoregulation effect that is contained in the composition that contains microorganism in the drinks manufacturing process.The lactobacillus bacterium preferably belongs to the lactobacillus bacterium of plant lactobacillus (Lactobacillus plantarum) or short lactobacillus (Lactobacillus brevis).
The mycology property of lactobacillus bacterium such as " in uncle's Jie Shi systematic bacteriology handbook (BERGEY ' S MANUAL ofSystematic Bacteriology) (the 1st volume 1984, the 2nd volume 1986, the 3rd volume 1989, the 4th volume 1989) record.
The representative bacterium of the milk-acid bacteria that the present invention relates to can be plant lactobacillus SAM2446 strain and short lactobacillus SAM2447 strain.This bacterium is preserved in Independent Administrative Leged Industrial Technology Complex Inst, the biological preservation of patent center (a kind of ground of 1 fourth order, east, ripple city, 1 central authorities the 6th are built in the Hitachinaka County, Japan), and its preserving number is FERMABP-10438 and FERM ABP-10439.The mycology property of plant lactobacillus SAM2446 strain (FERM ABP-10438) is as shown in table 1, and the mycology property of short lactobacillus SAM2447 strain (FERM ABP-10439) is as shown in table 2.
Table 1
Plant lactobacillus SAM 2446 strains (FERM ABP-10438)
Table 2
Short lactobacillus SAM 2447 strains (FERM ABP-10439)
Among the present invention, " have immunoregulation effect " and be meant when state or lower immune function usually, have immune activation effect (immunity effect effect) thereby or during immunologic hyperfunction immunosuppression form suitable immunological status effect (immunosuppressive action), make optimized active any effect at least of balance of cellular immunization and humoral immunization.Immunoregulation effect, for example can be promotion that cytokine produces or restraining effect, lymphocyte activation effect, the effect of NK (natural killer cell) increased activity, Th1/Th2 balance improvement effect, immunity reduces restraining effect, anti-allergic effects etc., but is not limited thereto.
Lactobacillus bacterium of the present invention, can by separate microorganism in the composition that contains microorganism from drinks manufacturing process, measure isolating each microorganism of institute immunoregulation effect, screen the strong bacterium of immunoregulation effect and obtain.
Among the present invention, " drinks manufacturing process " is meant with drinks and makes relevant series of processes.At this, also comprise the fruit wine of grape wine etc. in " drinks ", the fermented malt beverage of beer, sparkling wine etc., the liquor of pure mellow wine, whisky etc. etc.
The composition that contains microorganism is meant the composition that has microorganism in drinks manufacturing process, for example, and the raw material of blanking, karusen etc.
＜composition 〉
The lactobacillus bacterium that the present invention relates to can be used as the composition utilization that contains this lactobacillus bacterium.Particularly preferred as pharmaceutical compositions utilization with immunoregulation effect.
The lactobacillus bacterium that is contained in the above-mentioned composition can be lactobacillus bacterium (viable bacteria and dead bacterium), the lactobacillus bacterium contains thing, lactobacillus bacterium fermented product, lactobacillus bacterium handled thing etc.Viable bacteria can contain the thing from the lactobacillus bacterium of this lactobacillus bacteria culture fluid etc. and obtains.Dead bacterium, for example can by viable bacteria is heated, acquisitions such as uviolizing, formalin processing.Can make handled thing by resulting viable bacteria, dead bacterium are further ground, fragmentation etc.
Be the composition that contains the lactobacillus bacterium that utilizes the lactobacillus bacterium among the present invention, can contain lactobacillus bacterium, this lactobacillus bacterium that the present invention relates to contain in thing, this lactobacillus bacterium fermented product, this lactobacillus bacterium handled thing at least any one.Described lactobacillus bacterium contains thing, for example can be lactobacillus bacterium suspension, lactobacillus bacterium culture (comprising thalline, culture supernatant, medium component), lactobacillus bacteria culture fluid (remove from the bacterium culture solids component after product), lactobacillus bacterium fermented-milk (lactobacillus bacteria beverage, yogurt, sour milk etc.).Be used to cultivate the substratum of the microorganism that belongs to lactobacillus,, do not have restriction especially, all can use so long as belong to the substratum that the microorganism of lactobacillus can grow.And lactobacillus bacterium handled thing for example can be triturate, broken thing, fraction (extracting solution etc.), enriched material, mashed prod, dry thing (spraying drying thing, lyophilize thing, vacuum-drying thing, roller drying thing etc.), dilution etc.In addition, plant lactobacillus SAM2446 strain and short lactobacillus SAM2447 strain that cause the present invention relates to are isolating from the wine making operation, so, for example contain the material that makes the tunning of fruit vegetables, cereal fermentation by the lactobacillus bacterium that the present invention relates to, also as a kind of optimal way of the composition that contains milk-acid bacteria that utilizes the lactobacillus bacterium among the present invention.And as mentioned above, the lactobacillus bacterium that the present invention relates to is exactly isolating from food originally, so safe.
Utilize the composition that contains the lactobacillus bacterium of lactobacillus bacterium among the present invention, preferably use as pharmaceutical compositions with immunoregulation effect.For example can be diet product, pharmaceuticals, feed etc.When being used for the diet product, can preferably implement as heath food with immunoregulation effect.And the various compositions that can mix known sweeting agent, acidic flavoring agent, VITAMIN etc. are made the product that is fit to user's hobby.For example, can tablet, the form of milk-product of capsule, health-care nutrient liquor, lozenge, chewing gum, sour milk etc., ice-creams, beverage, alcoholic beverage, food flavouring, processed food, Dessert, dessert etc. provides.
When being used for pharmaceuticals, can in main ingredient, use in the pharmaceutical preparations technology fields such as vehicle, wedding agent, disintegrating agent, lubricant, drug flavoring, solubility promoter, suspension agent, coating material normally used known auxiliary carry out preparationization.Formulation can be tablet, capsule, granule, powder, syrup, suppository, injection etc., is not particularly limited.The route of administration of these pharmaceuticals for example can be oral administration, rectal administration, through enteral administration etc., but is not particularly limited.
When being used for feed, for example can mixing thalline in raw materials such as feeds, or also can make an addition in the commercially available animal feed in pet food or domestic animal.Wherein, can be preferred in the bait of birds such as dog, cat or chicken etc.
＜have a separation method of the milk-acid bacteria of immunoregulation effect 〉
The mensuration of immunoregulation effect can be used any method in the known method of those skilled in the art.For example, in the test of Th1 cytokines interleukin 12 (below be abbreviated as " IL-12 ") inducibility, to measure the generation of IL-12 by extracorporeal treatment by the peritoneal macrophage of mouse preparation.
The screening of the milk-acid bacteria that immunoregulation effect is strong can be undertaken by the strong bacterial strain of screening immunoregulation effect by the mensuration of above-mentioned immunoregulation effect.The standard of screening, can carry out with the milk-acid bacteria with known immunoregulation effect relatively, set with comparing or relatively wait suitably with mean value.In addition, except that immunoregulation effect, also can will whether show that general milk-acid bacteria good propagation adds in the screening criteria in substratum.
Among the present invention, " drinks manufacturing process " is meant with drinks and makes relevant series of processes.At this, also comprise the fruit wine of grape wine etc. in " drinks ", the fermented malt beverage of beer, sparkling wine etc., the liquor of pure mellow wine whisky etc. etc.
The composition that contains microorganism is meant the composition that has microorganism in drinks manufacturing process, for example is blanking raw material, karusen etc.
As separation source, by using fermentation liquid in the above-mentioned wine making operation etc., but the utmost point separates the milk-acid bacteria with immunoregulation effect efficiently.
Further describe the present invention by embodiment, but the invention is not restricted to the respective embodiments described above, in scope shown in the claim, can carry out all changes, for according to resulting embodiment after the different disclosed technique means of embodiment appropriate combination difference, also be contained in technical scope of the present invention.Embodiment
(use lactobacillus strain)
Be to select the strong bacterial strain of Th1 type immunity effect ability, will be from the wine making wine with dregs isolating 104 strains of lactic acid bacteria be used for the comparative experiments of interleukin 12 (IL-12) inducibility.
(IL-12 of stimulated in vitro induces)
To BALB/c mouse (7 ages in week are male), 4.05% sodium thioglycollate is carried out intraperitoneal administration, use PBS to reclaim the intraperitoneal scavenger cell after 4 days, use the RPMI substratum that contains 10%FBS to adjust to 2 * 10
6Behind the cells/mL, in the plate of 24 holes (well), add by every hole 0.5mL.In each hole, add the dead bacterium of heating (1 μ g/mL) of each bacterial strain, measure the IL-12 concentration in the culture supernatant of cultivating after 24 hours.Do not add dead bacterium in the contrast.Because of the active form of IL-12 be p35 and p40 subunit in conjunction with after p70, so measure IL-12 (p70).And use OptEIA mouse IL-12 to measure test kit (BDPharmingen corporate system) in the mensuration of IL-12.
The external IL-12 that estimates isolating 104 strains of lactic acid bacteria produces the result of ability, finds to contain in a large number to have the bacterial strain that IL-12 produces ability.Even comparing with known milk-acid bacteria with immunoregulation effect, the IL-12 of some of them bacterial strain generation ability also has very high activity.Wherein, have the IL-12 generation ability bacterial strain that exceeds 10 times of contrasts 12 strains are arranged, select so can be used as bacterial strain with high IL-12 generation ability.
Consider this high standard that exceeds 10 times of contrasts, think that this probability is quite high value, so, think that the wine making wine with dregs is highly beneficial with being worth as the separation source of immunomodulatory milk-acid bacteria.
Table 3
| The bacterial strain mark | The IL-12 generation is than (* 1) |
| Contrast | 1 |
| A(*2) | 45 |
| B | 37 |
| C | 36 |
| D | 32 |
| E | 31 |
| F | 25 |
| G | 25 |
| H | 23 |
| I | 20 |
| J | 19 |
| K | 13 |
| L(*3) | 13 |
* 1: with respect to the IL-12 generation of each sample of contrast
* 2: SAM 2446 strains described later (FERM ABP-10438)
* 3: SAM 2447 strains described later (FERM ABP-10439)
(use lactobacillus strain)
Milk-acid bacteria 12 strains of selecting among the embodiment 1 are used for the comparative experiments of body internal stimulus IL-12 inducibility.
(IL-12 of body internal stimulus induces)
To BALB/c mouse (7 ages in week are male), with the dead bacterium of the heating of above-mentioned each bacterial strain (500 μ g/0.2mL/mouse) suspension (solvent: normal saline solution) carry out intraperitoneal administration, after the cervical vertebra dislocation, take a blood sample after 6 hours from heart.Mouse equivalent for contrast is thrown to normal saline solution.After the blood sampling, take serum, use the IL-12 concentration in OptEIA mouse IL-12 mensuration test kit (BD Pharmingen corporate system) the mensuration serum by centrifugation.
The result as shown in Figure 1.Serum il-12 concentration is high especially in A strain and L strain.Therefore, with its called after SAM2446 strain respectively, SAM2447 strain.
The evaluation of embodiment 3 SAM2446 strains, SAM2447 strain
The result of study of the mycology property of SAM2446 strain is as shown in table 1, and the result of study of the mycology property of SAM2447 strain is as shown in table 2.
By these results of study, infer that the SAM2446 strain is plant lactobacillus, the SAM2447 strain is a short lactobacillus.The known plants Bacterium lacticum has and has sorbyl alcohol with voltinism with do not have sorbyl alcohol two kinds with voltinism, and as shown in table 1, the SAM2446 strain is to have the lactobacillus inoculation of sorbyl alcohol with voltinism.And known short lactobacillus has and has the D-wood sugar with voltinism with do not have D-wood sugar two kinds with voltinism, and as shown in table 2, the SAM2447 strain is not have the lactobacillus inoculation of D-wood sugar with voltinism.
After from SAM2446 strain and SAM2447 strain, extracting DNA, 16S rRNA gene region is understood.Because of the 16SrRNA gene order (sequence number 1) of the SAM2446 strain through understanding has homology with the 16SrRNA gene order 99% of plant lactobacillus JCM1149T (ATCC14917), so be accredited as plant lactobacillus (Fig. 2).And the 16SrRNA gene order of SAM2447 strain (sequence number 2) has the homology with the 16SrRNA gene order 97% of short lactobacillus JCM1059T (ATCC14869), so be accredited as short lactobacillus (Fig. 3).
The immunity effect and the immunoregulation effect of embodiment 4 oral uptakes
To C57BL/6 mouse [Japanese Charles River Co., Ltd. (Japanese original name: Japanese チ ヤ one Le ズ リ バ one Co., Ltd.), 7 ages in week male, 1 group 4], make its mode freely absorb 1 all SAM2446 strains, SAM2447 strain (extremely thalline) with drinking-water (being equivalent to 0.2mg/day).And the control group of SAM2446 strain, SAM2447 strain is not absorbed in setting.Extraction spleen after 1 week.According to usual method, prepare splenocyte with the spleen that extracts, measure the active and cytokine generation ability of NK.The active mensuration of NK is that splenocyte and target cell Yac-1 were cultivated 4 hours altogether with the ratio of 200: 1 or 100: 1, re-uses flow cytometer is measured splenocyte with the PINK method cytotoxic activity.And make concanavalin A (Nacalai Tesque) 2.5mg/mL and splenocyte (5 * 10
6Individual/as mL) to act on 24 hours, measure the IFN-γ concentration that produces in the culture supernatant with ELISA method [OptEIA (BD BioScience)].
The active measurement result of NK as shown in Figure 4.Among Fig. 4, NK activity (%) expression is to the cytotoxicity of mouse boosting cell Yac-1, the spleens cell number that E: T reacts than expression: Yac-1 number.Can illustrate that from Fig. 4 (control) compares with control group, by oral uptake the NK activity of splenocyte of mouse preparation of SAM2446 strain, SAM2447 strain significantly improve.
The measurement result of IFN-γ concentration as shown in Figure 5.Can illustrate that from Fig. 5 (control) compares with control group, by oral uptake the IFN-γ concentration of splenocyte of mouse preparation of SAM2446 strain, SAM2447 strain significantly increase.
As mentioned above, at oral uptake NK is active in the mouse of SAM2446 strain, SAM2447 strain increases, promoted the generation of Th1 cytokines IFN-γ.Therefore, prove that SAM2446 strain, SAM2447 strain have the immunity effect effect and have immunoregulation effect.
The manufacturing of embodiment 5 soyabean milk fermented products
Is that condition makes an addition in the commercially available soya-bean milk with SAM2446 strain zymocyte liquid not to be subjected to other microbial contaminations, and 30 ℃ leave standstill 24 hours acquisition soyabean milk fermented products.Fermentation is carried out rapidly, can find that acidity improves and the pH value reduces.Resulting fermented product is compared with plant fermentation product in the past and is not presented offending fermented flavour etc., and presents fragrance excellent on the sense organ.
Behind SAM2447 strain zymocyte liquid heat-sterilization, reclaim thalline by centrifugation (3000rpm, 10 minutes), resulting thalline carries out lyophilize.Stirring is added at this milk-acid bacteria thalline end in commercially available soya-bean milk, its suspension is dissolved in the soya-bean milk, the soya-bean milk at resultant interpolation milk-acid bacteria end is compared with the leavened food that contains milk-acid bacteria in the past, does not present unhappy fermented flavour etc., and presents fragrance excellent on the sense organ.
Embodiment 7 contains the manufacturing of the composition of milk-acid bacteria
Production Example 1: the pharmaceuticals that contain milk-acid bacteria
Tablet:
By method shown below, make the pharmaceuticals (tablet) that contain milk-acid bacteria.
50g SAM2446 strain thalline end is together mixed with 250g lactose and 2g Magnesium Stearate,, make the tablet of diameter 10mm, weight 300mg by using one-shot formula tabletting machine compressing tablet.
Granule:
In 100g SAM2447 strain thalline end, add the 0.5g Magnesium Stearate, compressed, pulverizing, whole grain, sieve after, obtain 20～50 purpose granules.
Production Example 2: the various diet product that contain milk-acid bacteria
With the composition shown in following, make the various diet product that added milk-acid bacteria.
Table 4
Sugar:
(composition) (weight part)
Sorbitol powder 99.7
Spices 0.2
SAM2446 strain thalline end 0.05
Sorbyl alcohol crystal seed (sorbitol seed) 0.05
Total amount 100.00
Table 5
Jelly (coffee jelly):
(composition) (weight part)
Refining white sugar 15.0
Gelatin 1.0
Coffee extract 5.0
Water 78.93
SAM2447 strain thalline end 0.07
Total amount 100.00
Table 6
Fruit juice:
(composition) (weight part)
Freeze concentration citrus unshiu Marcovitch fruit juice 5.0
Fructose Glucose Liquid sugar 11.0
Citric acid 0.2
L-xitix 0.02
SAM2446 strain thalline end 0.05
Spices 0.2
Pigment 0.1
Water 83.43
Total amount 100.00
Table 7
Soda pop:
(composition) (weight part)
Refining white sugar 8.0
Concentrate lemon juice 1.0
L-xitix 0.10
Citric acid 0.09
Trisodium Citrate 0.05
Colouring matter 0.05
Spices 0.15
Soda Ash Light 99.2min. 90.55
SAM2447 strain thalline end 0.01
Total amount 100.00
Table 8
Lactobacillus drink:
(composition) (weight part)
The fermented-milk 14.76 of milk solids composition 21%
Fructose Glucose Liquid sugar 13.31
Pectin 0.5
Citric acid 0.08
Spices 0.15
Water 71.14
SAM2446 strain thalline end 0.06
Total amount 100.00
Table 9
Lactobacillus drink:
(composition) (weight part)
The SAM2447 strain fermented-milk 14.82 of milk solids composition 21%
Fructose Glucose Liquid sugar 13.31
Pectin 0.5
Citric acid 0.08
Spices 0.15
Water 71.14
Total amount 100.00
Table 10
Coffee drinks:
(composition) (weight part)
Refining white sugar 8.0
Skim-milk 5.0
Caramel 0.2
Coffee extract 2.0
Spices 0.1
Polyglycerol fatty acid ester 0.05
Salt 0.05
Water 84.56
SAM2446 strain thalline end 0.04
Total amount 100.00
Table 11
Alcoholic beverage:
(composition) (weight part)
50 capacity % methyl alcohol 32.0
Granulated sugar 8.4
Fruit juice 2.4
SAM2447 strain thalline end 0.2
Purified Water 57.0
Total amount 100.0
Table 12
Sparkling wine:
(composition) (weight part)
Sparkling wine 99.98
SAM2447 strain thalline end 0.02
Total amount 100.0
Production Example 3: the feed that contains milk-acid bacteria
With composition as follows, make the feed that has added milk-acid bacteria.
Table 13
Feed:
(composition) (weight part)
Commercially available pet food 99.98
SAM2446 strain thalline end 0.02
Total amount 100.0
As absorb lactobacillus bacterium of the present invention etc., then can suppress lower immune function by composing immunologic function alive.And, can suppress organism is produced the various ill symptomses that bring to organism etc. of the excessive hyperfunction of dysgenic immunologic function and derivation thus by regulating the balance of immunologic function.According to the present invention, can efficiently obtain to have the milk-acid bacteria of immunoregulation effect.
Sequence table
SEQUENCE?LISTING
＜110〉Suntory Ltd (Suntory Limited)
＜120〉a kind of immune regulation composite that has the novel lactobacillus bacterium of immunoregulation effect and contain this bacterium
A?novel?Lactobacillus?bacterium?having?immunomodulationg?effects?and?a?composition
for?immunomodulation?containing?it
<130>YCT-1198
<160>4
<170>PatentIn?version?3.1
<210>1
<211>242
<212>DNA
＜213〉plant lactobacillus (Lactobacillus plantarum)
<400>1
atacatgcaa?gtcgaacgaa?ctctggtatt?gattggtgct?tgcatcatga?tttacatttg 60
agtgagtggc?gaactggtga?gtaacacgtg?ggaaacctgc?ccagaagcgg?gggataacac 120
ctggaaacag?atgctaatac?cgcataacaa?cttggaccgc?atggtccgag?tttgaaagat 180
ggcttcggct?atcacttttg?gatggtcccg?cggcgtatta?gctagatggt?ggggtaacgg 240
ct 242
<210>2
<211>353
<212>DNA
＜213〉plant lactobacillus (Lactobacillus plantarum)
<400>2
aggcggctgg?ttcctaaaag?gttaccccac?cgactttggg?tgttacaaac?tctcatggtg 60
tgacgggcgg?tgtgtacaag?gcccgggaac?gtattcaccg?cggcatgctg?atccgcgatt 120
actagcgatt?ccgacttcat?gtaggcgagt?tgcagcctac?aatccgaact?gagaatggct 180
ttaagagatt?agcttactct?cgcgagttcg?caactcgttg?taccatccat?tgtagcacgt 240
gtgtagccca?ggtcataagg?ggcatgatga?tttgacgtca?tccccacctt?cctccggttt 300
gtcaccggca?gtctcaccac?aatgcccaac?ttaatgctgg?caacagataa?taa 353
<210>3
<211>346
<212>DNA
＜213〉short lactobacillus (Lactobacillus brevis)
<400>3
aacgctggcg?gcatgcctaa?tacatgcaag?tcgaacgagc?ttccgttgaa?tgacgtgctt 60
gcactgattt?taacaatgaa?gcgagtggcg?aactggtgag?taacacgtgg?gaaatctgcc 120
cagaagcagg?ggataacact?tggaaacagg?tgctaatacc?gtataacaac?aaaatccgca 180
tggattttgt?ttgaaaggtg?gcttcggcta?tcacttctgg?atgatcccgc?ggcgtattag 240
ttagttggtg?aggtaaaggc?ccaccaagac?catgatgcgt?agccgacctg?agagggtaat 300
cgcccacatt?gggactggca?cacggcccat?actcctacgg?gaggca 346
<210>4
<211>524
<212>DNA
＜213〉short lactobacillus (Lactobacillus brevis)
<400>4
ctaatcatct?gtcccacctt?agacggctga?ctcccgaagg?ttatctcacc?ggctttgggt 60
gttacaaact?ctcatggtgt?gacgggcggt?gtgtacaagg?cccgggaacg?tattcaccgc 120
ggcatgctga?tccgcgatta?ctagcgattc?caacttcatg?taggcgagtt?gcagcctaca 180
atccgaactg?agaacggctt?taagagatta?gcttagcctc?acgacttcgc?gactcgttgt 240
accgtccatt?gtagcacgtg?tgtagcccag?gtcataaggg?gcatgatgat?ttgacgtcat 300
ccccaccttc?ctccggtttg?tcaccggcag?tctcaccaga?gtgcccaact?gaatgctggc 360
aactgataat?aagggttgcg?ctcgttgcgg?gacttaaccc?aacatctcac?gacacgagct 420
gacgacaacc?atgcaccacc?tgtcattctg?tccccgaagg?gaacgtctta?tctctaagat 480
tggcggaaga?tgtcaagacc?tggtaaggtt?cattcgcgta?gctt 524
Claims (5)
1. the plant lactobacillus (Lactobacillus plantarum) that has immunoregulation effect, described plant lactobacillus has the same voltinism of sorbyl alcohol, described plant lactobacillus is plant lactobacillus (Lactobacillus plantarum) SAM2446 strain, described SAM2446 strain is preserved in the biological preservation of Independent Administrative Leged Industrial Technology Complex Inst's patent center, and its deposit number is FERM BP-10438.
2. composition, it contains the bacterium described in the claim 1, has immunoregulation effect.
3. the composition described in the claim 2, wherein, described composition is the diet product.
4. the composition described in the claim 2, wherein, described composition is pharmaceuticals.
5. the composition described in the claim 2, wherein, described composition is a feed.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005317734 | 2005-10-31 | ||
| JP317734/2005 | 2005-10-31 | ||
| PCT/JP2006/321723 WO2007052643A1 (en) | 2005-10-31 | 2006-10-31 | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102384351A Division CN101914473B (en) | 2005-10-31 | 2006-10-31 | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101300341A CN101300341A (en) | 2008-11-05 |
| CN101300341B true CN101300341B (en) | 2011-05-11 |
Family
ID=38005796
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102384351A Expired - Fee Related CN101914473B (en) | 2005-10-31 | 2006-10-31 | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation |
| CN2006800406235A Expired - Fee Related CN101300341B (en) | 2005-10-31 | 2006-10-31 | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102384351A Expired - Fee Related CN101914473B (en) | 2005-10-31 | 2006-10-31 | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP4891255B2 (en) |
| KR (1) | KR101271379B1 (en) |
| CN (2) | CN101914473B (en) |
| TW (1) | TW200804591A (en) |
| WO (1) | WO2007052643A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008179601A (en) * | 2006-12-28 | 2008-08-07 | Suntory Ltd | Cosmetic composition containing bacterium of genus lactobacillus |
| JP5770425B2 (en) * | 2007-03-30 | 2015-08-26 | サントリーホールディングス株式会社 | Pharmaceutical composition or food or drink having a parasympathetic nerve activity enhancing action |
| ATE538667T1 (en) * | 2008-11-10 | 2012-01-15 | Nestec Sa | SIAL ACID PRODUCING BACTERIA |
| JP2010150206A (en) * | 2008-12-26 | 2010-07-08 | Kaneka Corp | Enteral nutrient having mucous membrane immuno-stimulation action and immuno-balance modulation action |
| JP5610472B2 (en) * | 2010-06-21 | 2014-10-22 | 学校法人酪農学園 | Novel lactic acid bacteria and novel lactic acid bacteria-containing composition |
| JP5927730B2 (en) * | 2013-04-11 | 2016-06-01 | アサヒグループホールディングス株式会社 | Screening method for lactic acid bacteria having immunomodulating action |
| KR101677463B1 (en) * | 2014-08-22 | 2016-11-21 | 영남대학교 산학협력단 | whitening cosmetic composition comprising extracts of fermented persimmon sludge |
| KR101879928B1 (en) * | 2016-02-19 | 2018-07-18 | 영남대학교 산학협력단 | Whitening cosmetic composition comprising fractions of persimmon extracts |
| KR102567791B1 (en) * | 2021-01-11 | 2023-08-17 | (주)지에프씨생명과학 | Lactobacillus plantarum GFC_B001 for removing hangover and food composition comprising the same as an effective ingredient |
| JP7225364B1 (en) | 2021-12-24 | 2023-02-20 | サンスター株式会社 | Lactic acid bacteria |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0755908B2 (en) * | 1992-11-24 | 1995-06-14 | 財団法人京都パストゥール研究所 | Immune function promoter |
| JPH092959A (en) * | 1995-06-16 | 1997-01-07 | Yakult Honsha Co Ltd | Immuno-globulin e antibody production suppressant and antiallergic agent |
| JP4064481B2 (en) * | 1996-10-11 | 2008-03-19 | ハウスウェルネスフーズ株式会社 | Immunostimulator |
| KR20020072807A (en) * | 2002-08-14 | 2002-09-18 | 주식회사 이롬라이프 | Novel lactobacillus sp. strain having the effect of immune enhancement |
| JP4034632B2 (en) * | 2002-10-01 | 2008-01-16 | ハウスウェルネスフーズ株式会社 | Composition for cooking rice containing lactic acid bacteria |
| JP2005139160A (en) * | 2003-03-13 | 2005-06-02 | Kirin Brewery Co Ltd | Antiallergic composition |
| JP2009002959A (en) | 2008-08-07 | 2009-01-08 | Nipro Corp | Specimen examination system |
-
2006
- 2006-10-31 WO PCT/JP2006/321723 patent/WO2007052643A1/en active Application Filing
- 2006-10-31 JP JP2007542752A patent/JP4891255B2/en active Active
- 2006-10-31 CN CN2010102384351A patent/CN101914473B/en not_active Expired - Fee Related
- 2006-10-31 KR KR1020087012297A patent/KR101271379B1/en not_active IP Right Cessation
- 2006-10-31 TW TW095140357A patent/TW200804591A/en unknown
- 2006-10-31 CN CN2006800406235A patent/CN101300341B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 姚晓英.乳酸杆菌的免疫治疗作用.国外医学（微生物学分册）.2004,27(5),28－30. * |
| 赵敏等.啤酒中乳酸杆菌的分离纯化和鉴定.酿酒.2005,32(1),58-60. * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW200804591A (en) | 2008-01-16 |
| WO2007052643A1 (en) | 2007-05-10 |
| KR20080065667A (en) | 2008-07-14 |
| JPWO2007052643A1 (en) | 2009-04-30 |
| CN101914473A (en) | 2010-12-15 |
| JP4891255B2 (en) | 2012-03-07 |
| CN101300341A (en) | 2008-11-05 |
| CN101914473B (en) | 2012-03-28 |
| KR101271379B1 (en) | 2013-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101300341B (en) | Lactic acid bacterium having immunoregulatory activity derived from moromi for wine fermentation | |
| Chaves‐López et al. | Traditional fermented foods and beverages from a microbiological and nutritional perspective: the Colombian heritage | |
| JP4346559B2 (en) | Fermented beverage and its production method | |
| US4056637A (en) | Process for preparing food products containing a lactic acid bacteria-fermented product of a cereal germ | |
| CN102770528B (en) | Method for constructing novel bacterium belonging to the genus bifidobacterium | |
| TWI563923B (en) | Ricebecue powder extract composition | |
| US20100098728A1 (en) | Immunostimulating composition containing Lactic Acid bacteria | |
| CN105249100B (en) | The production method of fermented fruits and vegetables juice and fermented glutinous rice beverage with compound functions | |
| KR101780176B1 (en) | Lactic acid bacterium proliferation promoter | |
| CN102971413A (en) | Novel lactobacillus classified as lactobacillus plantarum, and use thereof | |
| Kaur et al. | Traditional bio-preservation in beverages: Fermented beverages | |
| KR20150064360A (en) | Fruit Jam Comprising Fermented Stevia Extracts and Method for Preparing the Same | |
| JP2004215529A (en) | Method for producing lactic acid bacterium fermentation food product, beverage product, and seasoned food product all having good flavor and high gaba content | |
| US20220104523A1 (en) | Food and beverage products comprising ascomycetes | |
| JPWO2007052806A1 (en) | Method for producing fermented material containing GABA | |
| JP6955808B1 (en) | How to make fermented honey | |
| JP2020061977A (en) | Novel lactic acid bacterium that belongs to streptococcus salivarius, and use of the same | |
| JP2021164436A (en) | ONION WITH ENRICHED γ-AMINOBUTYRIC ACID AND CYCLOALLIIN AND METHOD FOR PRODUCING THE SAME | |
| JP2007006769A (en) | New lactic acid bacterium and beverage using the same | |
| JP2009195251A (en) | Fermented beverage and method for preparation of the same | |
| KR100630337B1 (en) | Process for preparing Opuntia ficus-indica fruit powder and milk product by fermentation | |
| KR20160121133A (en) | Three steps complex fermented crude liquid and manufacturing method thereof | |
| JP3618653B2 (en) | Pharmacological composition having blood pressure lowering effect | |
| JP4838628B2 (en) | Method for producing composition with high content of γ-aminobutyric acid | |
| JP2008050296A (en) | Physiologically active composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: SUNTORY HOLDINGS CO., LTD. Free format text: FORMER OWNER: SUNTORY LTD. Effective date: 20090626 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20090626 Address after: Osaka Japan Applicant after: Suntory Holdings Limited Address before: Osaka Japan Applicant before: Suntory Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110511 Termination date: 20161031 |